The Conversation (0)
Sierra Oncology received clearance from regulators in the UK to amend two ongoing Phase I trials on the company’s Chk 1 inhibitors, SRA737.
Sierra Oncology (NASDAQ:SRRA) received clearance from regulators in the UK to amend two ongoing Phase I trials on the company’s Chk 1 inhibitors, SRA737.
As quoted in the press release:
The amended trials will include cohort expansions of prospectively selected patients with tumors identified to have genetic aberrations hypothesized to confer sensitivity to Chk1 inhibition.
“Collaborating closely with our investigators and The Institute of Cancer Research, London, and The Royal Marsden in the UK, we have designed significant enhancements to our ongoing clinical trials for SRA737, which can now be implemented immediately and that are intended to enrich these studies with patients we believe are promising candidates for treatment with our drug,” said Dr. Nick Glover, President and CEO of Sierra Oncology. “Furthermore, between these two studies, we will have the opportunity to evaluate preliminary efficacy across seven distinct cancer indications exploring the possibility of inducing synthetic lethality with SRA737-driven inhibition of Chk1 in tumors with defined genetic alterations. An initial update from these trials is anticipated in early 2018.”
“Sierra is pursuing a leading-edge strategy for the development of SRA737 that thoughtfully leverages Chk1’s fundamental biological role in cancer and the DDR network with the objective of enhancing patient selection and maximizing potential responses. With the advancement of sophisticated genetic analysis tools, a novel genetically-driven clinical development approach such as this becomes feasible, furthering our progress towards personalized oncology therapy,” added the studies’ Chief Investigator Dr. Udai Banerji, Deputy Director of the Drug Development Unit at The Institute of Cancer Research and The Royal Marsden.
